{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:44:51Z","timestamp":1790963091081,"version":"4.1.0"},"reference-count":128,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,6,15]]},"abstract":"<jats:p> Thalidomide, initially introduced as a sedative, was withdrawn from the market in the early 1960s after it was found to be a teratogen. However, it later found use as an investigational agent in the treatment of erythema nodosum leprosum, oral ulcers, graft versus host disease, and wasting associated with the human immunodeficiency syndrome. Its antiangiogenic properties were recognized in the early 1990s during a period where the importance of angiogenesis became increasingly apparent as a critical step in the in the proliferation and spread of malignant neoplasms. This led to the evaluation of thalidomide as an antiangiogenic agent in the treatment of several cancers. Thalidomide has already become part of standard therapy for the treatment of patients with relapsed and refractory multiple myeloma. It has also been found to have varying degree of benefit in various other malignancies. Although more clinical trials are needed, Kaposi's sarcoma and myelofibrosis represent other malignancies in which thalidomide has already demonstrated promising activity. The mechanism of action of thalidomide in cancer is still unclear, but do appear to be mediated by several other mechanisms in addition to its anti-angiogenic properties. This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies. <\/jats:p>","DOI":"10.1200\/jco.2004.10.127","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T18:03:07Z","timestamp":1087322587000},"page":"2477-2488","source":"Crossref","is-referenced-by-count":72,"title":["Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies"],"prefix":"10.1200","volume":"22","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Lenz W: Thalidomide and congenital abnormalities. Lancet 1:45,1962,","DOI":"10.1016\/S0140-6736(62)92665-X"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)90927-8"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563303"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-6-199803150-00004"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705223362103"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199611000-00007"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3604.bloodjournal8693604"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88289-2"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.897"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.4065\/77.8.813"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1089\/152581602753448522"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Rogerson G: Thalidomide and congenital abnormalities. Lancet 1:691,1962,","DOI":"10.1016\/S0140-6736(62)92908-2"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563298"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563292"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757,1995-1763,","DOI":"10.1056\/NEJM199512283332608"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-689"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1997.0292"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001774660"},{"key":"R24","unstructured":"Chen TL, Vogelsang GB, Petty BG, et al: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 17:402,1989-405,"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1021\/js980172i"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2797"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010555"},{"key":"R28","unstructured":"Teo SK, Harden JL, Burke AB, et al: Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 29:1355,2001-1357,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1007\/BF00402227"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Stirling DI: Pharmacology of thalidomide. Semin Hematol 37:5,2000-14,","DOI":"10.1016\/S0037-1963(00)90077-5"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0939"},{"key":"R32","unstructured":"Lu J, Palmer BD, Kestell P, et al: Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 9:1680,2003-1688,"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100320"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Aweeka F, Trapnell C, Chernoff M, et al: Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. J Clin Pharmacol 41:1091,2001-1097,","DOI":"10.1177\/00912700122012698"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380303"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420460505"},{"key":"R37","unstructured":"Ghobrial IM, Rajkumar SV: Management of thalidomide toxicity. J Support Oncol 1:194,2003-205,"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.87"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431315"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442516"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0335"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200204000-00003"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04395_2.x"},{"key":"R45","unstructured":"Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377,2002-3382,"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00046-X"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00595.x"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1021\/jm960284r"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04605.x"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2263.h81802002263_2263_2265"},{"key":"R53","unstructured":"Haslett PA: Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25:53,1998-57,"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Gad SM, Shannon EJ, Krotoski WA, et al: Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 56:35,1985-39,","DOI":"10.5935\/0305-7518.19850006"},{"key":"R55","doi-asserted-by":"crossref","unstructured":"McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160,1995-167,","DOI":"10.1111\/j.1365-2249.1995.tb05527.x"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00050-X"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00084-7"},{"key":"R60","unstructured":"Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888,2001-1893,"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600817"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2000.22531"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2710"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1004"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1258\/0956462981921512"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2593"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2025"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.302"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10740"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf213"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020669705369"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.708"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006414804835"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012554328801"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.045"},{"key":"R76","unstructured":"Hwu WJ, Krown SE, Menell JH, et al: Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: A Phase II trial. Proc Am Soc Clin Oncol 21:344a,2002,  (abstr 1372)"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.039"},{"key":"R78","unstructured":"Reiriz AB, Richter M, Fernandes S, et al: A phase II study of thalidomide in patients with metastatic malignant melanoma. Proc Am Soc Clin Oncol 22:720,2003,  (abstr 2895)"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.061"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1429"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.950"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.950"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1159\/000039743"},{"key":"R84","unstructured":"Glass J, Gruber ML, Nirenberg A: Phase I\/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 18:551,1999,"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051103"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"R87","unstructured":"Govindarajan R: Irinotecan and thalidomide in metastatic colorectal cancer. Oncology (Huntingt) 14:29,2000-32,"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1147"},{"key":"R89","unstructured":"Mahmoud FA, Walsh D, Davis M, et al: A dose titration study of thalidomide in cancer anorexia. Proc Am Soc Clin Oncol 22:789,2003,"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.514"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.34"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04345.x"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200150"},{"key":"R94","unstructured":"Tricot G, Siegel E, Langmaid C, et al: Angiochemotherapy (ACT) for multiple myeloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control. Blood 98:3531a,2001,"},{"key":"R95","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006303"},{"key":"R96","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:4:219"},{"key":"R97","unstructured":"Offidani M, Mele A, Marconi M, et al: Thalidomide plus melphalan in relapsed-refractory multiple myeloma. Blood 98:5000a,2001,"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"R99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402866"},{"key":"R101","unstructured":"Stewart KA, Chen C, Howson-Jan K, et al: A randomized Phase II dose-finding trial of thalidomide and prednisone as maintenance therapy for myeloma following autologous stem cell transplant. Proc Am Soc Clin Oncol 21:269a,2002,  (abstr 1073)"},{"key":"R102","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf188"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50079"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50044"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.005"},{"key":"R106","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.834"},{"key":"R107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.958"},{"key":"R108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03204.x"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402330"},{"key":"R110","unstructured":"Pro B, Younes A, Albitar M, et al: Phase II Study of Thalidomide in Patients with Recurrent Hodgkin's Disease (HD) and Non-Hodgkin's Lymphomas (NHL). Blood 98:246b,2001,  (abstr 4712)"},{"key":"R111","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"R112","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402596"},{"key":"R113","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02918.x"},{"key":"R114","unstructured":"Seldin DC, Choufani E, Skinner M, et al: A phase I\/II trial of thalidomide for patients with AL Amyloidosis. Blood 98:164a,2001,  (abstr 691)"},{"key":"R115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3374.h8003374_3374_3380"},{"key":"R116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.4007"},{"key":"R117","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:2:79"},{"key":"R118","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040008"},{"key":"R119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"R120","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011141009812"},{"key":"R121","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402894"},{"key":"R122","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04252.x"},{"key":"R123","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(91)90093-9"},{"key":"R124","unstructured":"Perez-Atayde AR, Sallan SE, Tedrow U, et al: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815,1997-821,"},{"key":"R125","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509054750"},{"key":"R126","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01547.x"},{"key":"R127","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210190"},{"key":"R128","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03810.x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.10.127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:50:58Z","timestamp":1653511858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.10.127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,15]]},"references-count":128,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6,15]]}},"alternative-id":["10.1200\/JCO.2004.10.127"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.10.127","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,15]]}}}